...
机译:Vasohibin-1作为乳腺导管癌侵袭行为的潜在预测指标
Department of Surgical Oncology, Tohoku University Graduated School of Medicine, Miyagi;
Department of Pathology, Tohoku University Hospital, Miyagi;
Department of Pathology, Tohoku University Hospital, Miyagi;
Department of Pathology, Tohoku University Hospital, Miyagi;
Department of Surgical Oncology, Tohoku University Graduated School of Medicine, Miyagi|Department of Pathology, Tohoku University Hospital, Miyagi;
Department of Pathology 2, Kawasaki Medical School, Okayama;
Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University, Miyagi;
Department of Surgery, Tohoku Kosai Hospital, Miyagi;
Department of Breast Surgery, Nahanishi Clinic, Okinawa, Japan;
Department of Pathology, Tohoku University Hospital, Miyagi;
Department of Surgical Oncology, Tohoku University Graduated School of Medicine, Miyagi;
Department of Surgical Oncology, Tohoku University Gra;
机译:Vasohibin-1作为乳腺导管癌侵袭行为的潜在预测指标
机译:Vasohibin-1作为乳腺导管癌侵袭行为的潜在预测指标
机译:Vasohibin-1作为乳腺导管癌原位 I>侵袭行为的潜在预测因子
机译:弥散加权成像(DWI)用于挑战性导管原位癌(DCIS)和侵袭性小叶癌(ILC)的乳腺癌
机译:14-3-3 Zeta介导的上皮-间质转化(EMT)有助于ErbB2过表达导管原位癌(DCIS)演变为浸润性乳腺癌
机译:乳腺导管原位癌微浸润导管癌和浸润性乳腺癌的分布不同
机译:vasohibin-1作为导管癌原位乳腺癌侵蚀行为的潜在预测因子